W
Westlake Therapeutics
Developing a variety of innovative cell therapy products for rare diseases
About Westlake Therapeutics
Westlake Therapeutics (Hangzhou) Co., Ltd. is a biotechnology firm established in June 2020, operating from Hangzhou, China. It was the first spin-off company from Westlake University and was founded by Dr. Xiaofei Gao. Dr. Gao earned his Ph.D. from the University of Kansas and conducted postdoctoral research at the Massachusetts Institute of Technology before joining Westlake University in 2017 to focus on cellular drug development. His work led to the creation of the REDx therapeutic platform, a core technology for the company.
The company centers its operations on developing therapies based on engineered Red Blood Cells (RBC). This approach is applied to a wide range of human diseases, including cancers, as well as immunological and metabolic disorders. The business model revolves around the research, development, and eventual commercialization of these cell therapies. Westlake Therapeutics establishes collaborations with hospitals, medical research institutes, and other biotech companies to advance its clinical research. The company has secured significant venture capital, having raised nearly 300 million RMB to fund its R&D, team expansion, and infrastructure development.
Westlake Therapeutics' core product is its proprietary REDx platform, which engineers RBCs to function as therapeutic agents. This technology involves modifying either stem cell-derived or natural RBCs to carry various drug modalities. The process includes isolating erythrocytes, attaching drugs to them using linkers, and creating an Erythrocyte-drug-Conjugate (EDC). These engineered cells are then cultivated ex vivo in large numbers before being reintroduced into patients. A key benefit of this platform is its potential to create off-the-shelf cellular products at a lower cost. The company's pipeline features several first-in-class candidates for personalized transfusions and treatments. One of its lead products, WTX-212, an Erythrocyte-αPD-1 antibody conjugate, is in clinical trials for cancer patients who have not responded to conventional immunotherapy and has shown promising results.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $28M | $110M | Efung Capital · Real Power Capital · HongShan · Suzhou International Development Venture Capital Holding | ↗ |
| LATE VCOther financing | Jul 2021 | $14M | $55M | Sequoia · Fang Group · CD Capital | — |
Growth signals
Latest recorded traffic for Westlake Therapeutics is 900 monthly website visits, up 462.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Westlake Therapeutics in the Hangzhou ecosystem
The Westlake Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Series B and later1 investor entered at this stage
- FGFang Group
Other known investors2 additional known investors
University of Chinese Academy of Sciences
Westlake University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Westlake Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Westlake Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.















